Daiichi Sankyo has entered into a partnership with Ultragenyx Pharmaceutical for the use of Ultragenyx’s proprietary AAV-based gene-therapy manufacturing technology.
Daiichi Sankyo, a pharmaceutical company based in Japan, announced on April 1, 2020 that it has entered into a partnership with Ultragenyx Pharmaceutical, a clinical-stage biopharmaceutical company located in Novato, CA, for use of Ultragenyx’s proprietary adeno associated virus (AAV)-based gene therapy manufacturing technology.
Through the agreement, Daiichi Sankyo will provide an upfront payment of $125 million to Ultragenyx along with additional payments of $25 million for technology transfer and sales royalties of products manufactured by Ultragenyx’s technology, and $75 million for Ultragenyx’s common stock, a Daiichi Sankyo press release said.
Following the technology transfer, Daiichi Sankyo plans to expand its manufacturing capacity by starting the manufacture of investigational drugs for AAV gene therapy by the middle of 2020 with Ultragenyx’s assistance, according to the press release.
Source: Daiichi Sankyo
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.